X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

SAVOR-TIMI 53 sets new standard for cardiovascular outcome trials in diabetes

Yuvraj_pawp by Yuvraj_pawp
4th September 2013
in Americas, News

Uncertainty persists regarding whether drugs that lower sugar reduce the risk of heart attack, with some concerns that diabetes drugs may actually raise the risks.

The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR-TIMI 53) trial was a large international clinical trial that randomized patients to the diabetes drug saxagliptin (Onglyza), a selective dipeptidyl peptidase 4 (DPP-4) inhibitor, or to placebo in order to determine the effect on heart attack risk. The study found no excess, or reduction, in the risk of the primary composite endpoint of heart attacks, stroke, or cardiovascular death, which was the primary safety goal of the study. An increase in hospitalization for heart failure in the saxagliptin arm was noted.

“This large cardiovascular outcome trial sets a new standard for examination of the safety of diabetes drugs,” said trial co-principal investigator, Deepak L. Bhatt, MD, MPH, from the VA Boston Healthcare System and the TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, USA.

“Saxagliptin demonstrated better control of glucose compared with placebo, reduced the need for insulin therapy, and prevented deterioration in protein spilling from the kidneys to the urine,” added co-principal investigator Itamar Raz, MD, Hadassah Medical Center, Israel.

SAVOR-TIMI 53, a multicenter, randomized, double-blind, placebo-controlled Phase 4 trial conducted at 788 sites in 26 countries, included patients with type 2 diabetes mellitus, HbA1c levels between 6.5% and 12.0%, and either established or multiple risk factors for cardiovascular disease.

A total of 16,492 patients were randomized to receive either saxagliptin 5 mg daily (or 2.5 mg daily in patients with renal impairment) or matching placebo over a median follow-up of 2.1 years. Treatment with all other diabetes and cardiovascular medications was left to the discretion of the treating physician.

The primary endpoint of the study, a composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal ischemic stroke occurred in 7.3% of the saxagliptin group compared with 7.2% of the placebo group (hazard ratio [HR] 1.00; P =0.99 for superiority and P <0.001 for non-inferiority).

The major secondary endpoint of cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure, unstable angina or coronary revascularization was also balanced and occurred in 12.8% of the saxagliptin group and 12.4% of the placebo group (HR 1.02; P=0.66).

“The lack of any excess in heart attack risk is reassuring,” commented Benjamin Scirica, MD MPH, TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, USA, “though the neutral findings are in contrast to the benefit observed in pooled analyses from smaller, prior studies of saxagliptin, and highlight the importance of adequately powered outcome studies with sufficient follow-up to assess more fully cardiovascular effects of therapy.”

In terms of blood sugar control, patients treated with saxagliptin were more likely to achieve a glycated hemoglobin less than 7% at the end of treatment (36.2% vs. 27.9%; P<0.001).

However, significantly more patients in the saxagliptin group reported at least one hypoglycemic event compared with placebo (15.3% vs 13.4%; p<0.001), though there was no significant excess in the rate of hospitalization for hypoglycemia.

Additionally, more patients in the saxagliptin group were hospitalized for heart failure compared with the placebo group (3.5% vs 2.8%; HR 1.27; P=0.007).

“The increase in hospitalization for heart failure was not expected and deserves further study,” stated study chairman Eugene Braunwald, MD, TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, USA.

Tags: America
Previous Post

Novartis holds annual healthcare entrepreneur competition

Next Post

Statins being overprescribed for growing number of kidney disease patients

Related Posts

Lonza To Construct $518mn Fill-Finish Plant In Switzerland
Manufacturing

Lonza To Construct $518mn Fill-Finish Plant In Switzerland

8th July 2022
Pfizer And Touchlight Enter Into A Patent Collaboration
Manufacturing

Pfizer And Touchlight Enter Into A Patent Collaboration

8th July 2022
AstraZeneca, GSK Weathered Q2 Storm, But Roche Stock Plunged
Manufacturing

AstraZeneca, GSK Weathered Q2 Storm, But Roche Stock Plunged

8th July 2022
Paxlovid Allowed By FDA To Sell At Certified Pharmacies
Manufacturing

Paxlovid Allowed By FDA To Sell At Certified Pharmacies

8th July 2022
Deloitte Believes Mature R&D Firms Reap Enterprise Value
Manufacturing

Deloitte Believes Mature R&D Firms Reap Enterprise Value

7th July 2022
Dupixent From Sanofi Delivers Another Fantastic Performance
Manufacturing

Sanofi Sets Up Fund To Enable Firms In Low-Income Countries

5th July 2022
Next Post

Statins being overprescribed for growing number of kidney disease patients

Latest News

Lonza To Construct $518mn Fill-Finish Plant In Switzerland
Manufacturing

Lonza To Construct $518mn Fill-Finish Plant In Switzerland

8th July 2022
Pfizer And Touchlight Enter Into A Patent Collaboration
Manufacturing

Pfizer And Touchlight Enter Into A Patent Collaboration

8th July 2022
AstraZeneca, GSK Weathered Q2 Storm, But Roche Stock Plunged
Manufacturing

AstraZeneca, GSK Weathered Q2 Storm, But Roche Stock Plunged

8th July 2022
Paxlovid Allowed By FDA To Sell At Certified Pharmacies
Manufacturing

Paxlovid Allowed By FDA To Sell At Certified Pharmacies

8th July 2022
Deloitte Believes Mature R&D Firms Reap Enterprise Value
Manufacturing

Deloitte Believes Mature R&D Firms Reap Enterprise Value

7th July 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In